文献速递神经肿瘤

优化临床前儿童低级别胶质瘤模型以实现有意义的临床转化

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
PubMed 文献 · Neuro Oncol · 2023-01-01

儿童低级别胶质瘤(pLGG)是最常见的儿童脑肿瘤,虽总生存良好但常伴慢性肿瘤及治疗相关疾病。pLGG由汇聚于MEK/ERK通路的基因改变引起,其生长受局部微环境中非肿瘤细胞影响。本文作为pLGG白皮书系列之一,讨论临床前pLGG建模现状,以期改善临床转化。

要点

  • pLGG由汇聚于MEK/ERK通路的基因改变引起,但生长受神经元、T细胞、小胶质细胞等微环境非肿瘤细胞影响。
  • 不可切除pLGG患者常多次复发并持续存在神经系统症状。
  • 需使用预测性临床前模型来识别最有希望的候选药物以供临床评估。

核心结论

  • 讨论临床前pLGG建模现状,目标是改善这些常见儿童脑肿瘤的临床转化。

研究设计与样本

  • 作为聚焦pLGG的白皮书系列之一,讨论临床前pLGG建模的当前状态。

主要发现

  • pLGG是幼儿最常见的脑肿瘤,通常总生存良好,但患儿常经历慢性肿瘤和治疗相关疾病。
  • 不可切除肿瘤个体频繁多次复发并持续存在神经系统症状。
  • pLGG的深度分子分析显示其由汇聚于单一促分裂原通路(MEK/ERK)的基因改变引起。
  • pLGG生长受局部微环境中非肿瘤细胞(神经元、T细胞、小胶质细胞)的强烈影响。
  • 肿瘤细胞MEK/ERK通路激活与基质细胞支持的相互作用,要求使用预测性临床前模型来识别最有希望的候选药物以供临床评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in young children. While they are typically associated with good overall survival, children with these central nervous system tumors often experience chronic tumor- and therapy-related morbidities. Moreover, individuals with unresectable tumors frequently have multiple recurrences and persistent neurological symptoms. Deep molecular analyses of pLGGs reveal that they are caused by genetic alterations that converge on a single mitogenic pathway (MEK/ERK), but their growth is heavily influenced by nonneoplastic cells (neurons, T cells, microglia) in their local microenvironment. The interplay between neoplastic cell MEK/ERK pathway activation and stromal cell support necessitates the use of predictive preclinical models to identify the most promising drug candidates for clinical evaluation. As part of a series of white papers focused on pLGGs, we discuss the current status of preclinical pLGG modeling, with the goal of improving clinical translation for children with these common brain tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Milde T, Fangusaro J, Fisher MJ, et al. Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation. Neuro Oncol. 2023. PMID: 37738646. doi:10.1093/neuonc/noad125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。